1. Review obesity and diabetes trends and health disparities in the US 2. Review body image and perception differences by race/ethnicity 3. Describe best practices in the treatment of diabetes in African Americans 4. Examine the difference in HbA1c interpretations in African Americans and related clinical considerations

The American Diabetes Association (ADA) has recently updated their guidelines for pharmacologic management of T2DM which addresses patients with various co-morbid conditions. This episode will overview these guidelines to help primary care clinicians hone treatment of their patients with T2DM.

Join us as we discuss key points from the 2019 update to the American Diabetes Association and the European Association for the Study of Diabetes consensus report. This update is now reflected in the American Diabetes Association's Standards of Medical Care—2020.

Listen to this podcast for a concise summary of the latest clinical practice guidelines for identifying glycemic targets and managing T2DM in various patient populations including, older adults, individuals with increased cardiac or renal risk, and those at risk for hypoglycemic events.

When patients with T2DM have difficulty controlling their glucose with standard approaches, or are newly diagnosed but severely hyperglycemic, insulin is commonly used to help control their metabolism. Using long acting, once a day agents is a standard of care but in the last 15 years, the costs of insulin has skyrocketed. During this episode we will review a study examining the effects of using Neutral Protamine Hagedorn Insulin (NPH) rather than once a day insulin on A1c control and risk for hypoglycemia and discuss their findings, which suggest NPH can be used with equivalent glycemic control and with no additional risk.

This short curriculum cuts to the heart of primary and secondary cardiovascular disease prevention in people with type 2 diabetes. The following two activities will help you individualize treatment and optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences. This curriculum includes: • 1 educational video webcast • 1 simulated digital “tele-visit” with a standardized patient Pri-Med has partnered with RealCME to offer the Pri-Med community the innovative opportunity to schedule time for a simulated digital “tele-visit” with a standardized patient (SP), who is trained to simulate the symptoms and characteristics of patients you see in your practice. This interactive session is designed to complement the “Heart of the Matter” video webcast by enabling you to practice shared-decision making. You can benefit from scheduling this activity after viewing the educational webcast, but you are also welcome to sign up for this simulated digital tele-visit activity without viewing the webcast. The “patient” is a 52-year-old who is following up with you for their type 2 diabetes, with a history of obesity, hypertension, hypercholesterolemia, and coronary artery disease. The patient is on maximum dose of metformin, with an A1c today of 8.6%. A highly experienced observer will review your session and send you feedback via a customized scorecard. There is no cost for this activity, but there are limited sessions available. To schedule your free virtual visit, you will need this access code: PriMed2020 Link to activity: https://m.pri-med.com/T1ZMR080r000iMb30E5hYA0 Access code: PriMed2020

This podcast series will provide you with on the go learning covering the key points about GLP-1 receptor agonists (GLP-1 RAs). Dr. Michelle Magee will focus on barriers that patients may face to starting a GLP-1 RA and common questions that emerge in patient teaching. Cardiologist Ty Gluckman will take a deep dive into the cardiology benefits and indications for GLP-1 RAs. A FAQ session with Dr. Richard Pratley will answer Pri-Med learner questions about GLP-1 RAs.

Continuous glucose monitoring (CGM) is at the forefront of new diabetes technologies and can lead to improved care for many people, but the expanding market challenges primary care clinicians to keep up with guidelines on how and when to use personal and professional CGM devices. This curriculum, developed in partnership with the Association of Diabetes Care and Education Specialists (ADCES), will educate clinicians on how to identify people who are candidates for CGM, interpret CGM data, and adjust treatment plans, while effectively involving patients in these decisions. These practical strategies and insights for using CGM will help transform this new technology from a specialty-based tool to an integral part of diabetes management in the primary care setting. You can earn up to 2.0 CME/CE credits in total by completing all 3 of the modules in this curriculum. Two podcasts are also included that are designed to share with patients who want to know more about CGM; they do not qualify for CME/CE credit. This curriculum includes: • A series of 3 text-based adaptive learning modules • 2 Patient education podcasts (~15-20 minutes each)

Continuous glucose monitoring (CGM) is at the forefront of new diabetes technologies and can lead to improved care for many people with Type I and Type II Diabetes. However, the expanding diabetes market challenges primary care clinicians to keep up with guidelines on how and when to use personal and professional CGM devices. This session, developed in partnership with the Association of Diabetes Care and Education Specialists (ADCES), will educate clinicians on how to identify people who are candidates for CGM, interpret CGM data, and adjust treatment plans, while effectively involving patients in these decisions. These practical strategies and insights for using CGM will help transform this new technology from a specialty-based tool to an integral part of diabetes management in the primary care setting. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 9/10/20, and they are subject to change as new information is published.

Over ten percent of the U.S. population suffers disproportionate cardiometabolic risk because of their type 2 diabetes (T2DM). In light of recent data, GLP-1 receptor agonists (GLP-1 RAs) have taken on a more prominent role in T2DM management algorithms. This session will discuss how you can distinguish among GLP-1 RAs and use them in your practice to help manage the risks that these patients face beyond glucose control. A member of the Diabetes Sisters organization will also be joining us to discuss their experience with starting a GLP-1 RA as a patient.

Dr. Martin Abrahamson will review the pathophysiology of type 2 diabetes, discuss non-insulin treatments, and explore the most recent guidelines and recommendations for advancing treatment in people with type 2 diabetes to achieve glycemic goals. Dr. Frank Domino will then review a basic framework for counseling patients on weight loss, including a discussion of best evidence on diet, exercise, and appropriate use of medication. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 12/03/2020, and they are subject to change as new information is published.